Boissel et al. [122] demonstrated that at the time of diagnosis, patients with CML had abnormally high levels of soluble forms of MIC (sMIC) in the serum and poor NKG2D expression on NK and CD8+ T lymphocytes, which were restored by imatinib therapy. The gene discussed is KLRK1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.